Novo Nordisk To Pay $2 Billion for New Weight Loss Drug
TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March 24. The drug, called UBT251, is being developed by United Bio-Technology (Hengqin) Co., a Chinese pharmaceutical company.
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...
Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a ...
Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of ...
Zacks.com on MSN8h
Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy ...
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
Novo Nordisk has updated its Wegovy savings program, allowing eligible cash-paying patients to access the drug at retail ...
6hon MSN
The two stocks have been trending in different directions for months. Here's what that says about the broader market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback